Frontiers in Oncology | Cancer Molecular Targets and Therapeutics

Original Research

Published on 14 Sep 2023

LTe2 induces cell apoptosis in multiple myeloma by suppressing AKT phosphorylation at Thr308 and Ser473

in Cancer Molecular Targets and Therapeutics

Yuanjiao Zhang
Jiacheng Qian
Mingmei Jiang
Shu Yang
Lianxin Zhou
Qin Zhang
Liping Lin
Ye Yang

Frontiers in Oncology

doi 10.3389/fonc.2023.1269670

1,553 views
1 citation

Hypothesis and Theory

Published on 14 Sep 2023

Opioids and immune checkpoint inhibitors differentially regulate a common immune network in triple-negative breast cancer

in Cancer Molecular Targets and Therapeutics

Joseph R. Scarpa
Giacomo Montagna
George Plitas
Amitabh Gulati
Gregory W. Fischer
Joshua S. Mincer

Frontiers in Oncology

doi 10.3389/fonc.2023.1267532

2,110 views
4 citations

Original Research

Published on 13 Sep 2023

System analysis based on the lysosome-related genes identifies HPS4 as a novel therapy target for liver hepatocellular carcinoma

in Cancer Molecular Targets and Therapeutics

Ke‐Jie He
Zhiqiang Nie

Frontiers in Oncology

doi 10.3389/fonc.2023.1221498

1,696 views
1 citation

Review

Published on 12 Sep 2023

Cellular senescence: a double-edged sword in cancer therapy

in Cancer Molecular Targets and Therapeutics

Shuai Xiao
Dongmin Qin
Xueyang Hou
Lingli Tian
Yeping Yu
Rui Zhang
Hao Lyu
Dong Guo
Xing-Zhen Chen
Cefan Zhou

Frontiers in Oncology

doi 10.3389/fonc.2023.1189015

12,164 views
34 citations

Review

Published on 08 Sep 2023

Single domain Camelid antibody fragments for molecular imaging and therapy of cancer

in Cancer Molecular Targets and Therapeutics

Shulin Li
Sanne Johanna Maria Hoefnagel
Kausilia Krishnawatie Krishnadath

Frontiers in Oncology

doi 10.3389/fonc.2023.1257175

4,056 views
2 citations

Original Research

Published on 08 Sep 2023

Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma

in Cancer Molecular Targets and Therapeutics

Kristina Breitenecker
Viola Hedrich
Franziska Pupp
Doris Chen
Eva Řezníčková
Gregor Ortmayr
Heidemarie Huber
Gerhard Weber
Lorenz Balcar
Matthias Pinter

Frontiers in Oncology

doi 10.3389/fonc.2023.1238883

2,939 views
3 citations

Original Research

Published on 07 Sep 2023

CAR requires Gadd45β to promote phenobarbital-induced mouse liver tumors in early stage

in Cancer Molecular Targets and Therapeutics

Takeshi Hori
Kosuke Yokobori
Rick Moore
Masahiko Negishi
Tatsuya Sueyoshi

Frontiers in Oncology

doi 10.3389/fonc.2023.1217847

1,749 views
3 citations

Original Research

Published on 06 Sep 2023

Pan-cancer analysis identified OAS1 as a potential prognostic biomarker for multiple tumor types

in Cancer Molecular Targets and Therapeutics

Shan Jiang
Xinzhou Deng
Ming Luo
Le Zhou
Jingjing Chai
Chao Tian
Yutao Yan
Zhiguo Luo

Frontiers in Oncology

doi 10.3389/fonc.2023.1207081

3,128 views
6 citations

Case Report

Published on 06 Sep 2023

Case Report: Cancer spectrum and genetic characteristics of a de novo germline POLD1 p.L606M variant-induced polyposis syndrome

in Cancer Molecular Targets and Therapeutics

Ying Zhang
Xiaolu Wang
Yuning Zhu
Chong Liang
Lijun Zhao
Qi Meng
Jiani C. Yin
Yuqian Shi
Fufeng Wang
Feng Qin

Frontiers in Oncology

doi 10.3389/fonc.2023.1222873

2,059 views

Original Research

Published on 06 Sep 2023

Development and validation of novel immune-inflammation-based clinical predictive nomograms in HER2-negative advanced gastric cancer

in Cancer Molecular Targets and Therapeutics

Yan Yang
Yu Shao
Junjun Wang
Qianqian Cheng
Hanqi Yang
Yulong Li
Jing Liu
Yangyang Zhou
Zhengguang Zhou
Mingxi Wang

Frontiers in Oncology

doi 10.3389/fonc.2023.1185240

1,722 views
2 citations

Review

Published on 06 Sep 2023

Diagnostics and treatment of ovarian cancer in the era of precision medicine - opportunities and challenges

in Cancer Molecular Targets and Therapeutics

Patrycja Aleksandra Bukłaho
Joanna Kiśluk
Jacek Nikliński

Frontiers in Oncology

doi 10.3389/fonc.2023.1227657

5,250 views
4 citations

Original Research

Published on 01 Sep 2023

Cross-species evaluation of fibroblast activation protein alpha as potential imaging target for soft tissue sarcoma: a comparative immunohistochemical study in humans, dogs, and cats

in Cancer Molecular Targets and Therapeutics

Patricia Beer
Chantal Pauli
Martina Haberecker
Paula Grest
Erin Beebe
Daniel Fuchs
Enni Markkanen
Christiane Krudewig
Mirja Christine Nolff

Frontiers in Oncology

doi 10.3389/fonc.2023.1210004

2,904 views
1 citation

Original Research

Published on 31 Aug 2023

GRPR versus PSMA: expression profiles during prostate cancer progression demonstrate the added value of GRPR-targeting theranostic approaches

in Cancer Molecular Targets and Therapeutics

Marjolein Verhoeven
Eline A. M. Ruigrok
Geert J. L. H. van Leenders
Lilian van den Brink
Hayri E. Balcioglu
Wytske M. van Weerden
Simone U. Dalm

Frontiers in Oncology

doi 10.3389/fonc.2023.1199432

3,482 views
8 citations

Original Research

Published on 31 Aug 2023

Molecular profiling and specific targeting of gemcitabine-resistant subclones in heterogeneous pancreatic cancer cell populations

in Cancer Molecular Targets and Therapeutics

Benedikt Färber
Olga Lapshyna
Axel Künstner
Michael Kohl
Thorben Sauer
Kira Bichmann
Benjamin Heckelmann
Jessica Watzelt
Kim Honselmann
Louisa Bolm

Frontiers in Oncology

doi 10.3389/fonc.2023.1230382

2,936 views
2 citations

Original Research

Published on 31 Aug 2023

MiR-4270 acts as a tumor suppressor by directly targeting Bcl-xL in human osteosarcoma cells

in Cancer Molecular Targets and Therapeutics

Clément Veys
Flavie Boulouard
Abderrahim Benmoussa
Manon Jammes
Emilie Brotin
Françoise Rédini
Laurent Poulain
Nicolas Gruchy
Christophe Denoyelle
Florence Legendre

Frontiers in Oncology

doi 10.3389/fonc.2023.1220459

1,465 views
2 citations

Original Research

Published on 30 Aug 2023

miRNome expression analysis in canine diffuse large B-cell lymphoma

in Cancer Molecular Targets and Therapeutics

Nelly O. Elshafie
Michael Gribskov
Nathanael I. Lichti
Ekramy. E. Sayedahmed
Michael O. Childress
Andrea P. dos Santos

Frontiers in Oncology

doi 10.3389/fonc.2023.1238613

2,421 views
4 citations

Navigation group

Articles

LTe2 induces cell apoptosis in multiple myeloma by suppressing AKT phosphorylation at Thr308 and Ser473

Opioids and immune checkpoint inhibitors differentially regulate a common immune network in triple-negative breast cancer

System analysis based on the lysosome-related genes identifies HPS4 as a novel therapy target for liver hepatocellular carcinoma

Cellular senescence: a double-edged sword in cancer therapy

Single domain Camelid antibody fragments for molecular imaging and therapy of cancer

Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma

CAR requires Gadd45β to promote phenobarbital-induced mouse liver tumors in early stage

Pan-cancer analysis identified OAS1 as a potential prognostic biomarker for multiple tumor types

Case Report: Cancer spectrum and genetic characteristics of a de novo germline POLD1 p.L606M variant-induced polyposis syndrome

Development and validation of novel immune-inflammation-based clinical predictive nomograms in HER2-negative advanced gastric cancer

Diagnostics and treatment of ovarian cancer in the era of precision medicine - opportunities and challenges

Cross-species evaluation of fibroblast activation protein alpha as potential imaging target for soft tissue sarcoma: a comparative immunohistochemical study in humans, dogs, and cats

GRPR versus PSMA: expression profiles during prostate cancer progression demonstrate the added value of GRPR-targeting theranostic approaches

Molecular profiling and specific targeting of gemcitabine-resistant subclones in heterogeneous pancreatic cancer cell populations

MiR-4270 acts as a tumor suppressor by directly targeting Bcl-xL in human osteosarcoma cells

miRNome expression analysis in canine diffuse large B-cell lymphoma